Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Heath

Showing results (171-180 of 248) with videos related to

Pageof 25
Sort By:
Cancer Immunology Research|February 27, 2026
Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid TumorsJohn R Lozada, Atef Ali, Christine Luo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagusE I Heath, B A Burtness, R F Heitmiller, et al.
Urology|February 5, 2008
The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancerElisabeth I Heath, Michael W Kattan, Isaac J Powell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate CancerRahul R Aggarwal, Michael T Schweizer, David M Nanus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2019
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 TherapyJonathan E Rosenberg, Peter H O'Donnell, Arjun V Balar, et al.
Urologic Oncology|June 6, 2022
Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomesEarle F Burgess, J Alexa Sanders, Chad Livasy, et al.
Investigational New Drugs|February 28, 2006
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinomaElisabeth I Heath, Barbara A Burtness, Lawrence Kleinberg, et al.
Human Genetics|July 2, 2009
Results from a prostate cancer admixture mapping study in African-American menCathryn Hufford Bock, Ann G Schwartz, Julie J Ruterbusch, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 18, 2018
Tissue-specific regulation of cytochrome c by post-translational modifications: respiration, the mitochondrial membrane potential, ROS, and apoptosisHasini A Kalpage, Viktoriia Bazylianska, Maurice A Recanati, et al.
Cancer Research|March 15, 2008
Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibitionDuyen T Dang, Sang Y Chun, Kyunghee Burkitt, et al.
Pageof 25

Showing results (171-180 of 248) with videos related to

Sort By:
Pageof 25
Cancer Immunology Research|February 27, 2026
Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid TumorsJohn R Lozada, Atef Ali, Christine Luo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagusE I Heath, B A Burtness, R F Heitmiller, et al.
Urology|February 5, 2008
The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancerElisabeth I Heath, Michael W Kattan, Isaac J Powell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate CancerRahul R Aggarwal, Michael T Schweizer, David M Nanus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2019
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 TherapyJonathan E Rosenberg, Peter H O'Donnell, Arjun V Balar, et al.
Urologic Oncology|June 6, 2022
Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomesEarle F Burgess, J Alexa Sanders, Chad Livasy, et al.
Investigational New Drugs|February 28, 2006
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinomaElisabeth I Heath, Barbara A Burtness, Lawrence Kleinberg, et al.
Human Genetics|July 2, 2009
Results from a prostate cancer admixture mapping study in African-American menCathryn Hufford Bock, Ann G Schwartz, Julie J Ruterbusch, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 18, 2018
Tissue-specific regulation of cytochrome c by post-translational modifications: respiration, the mitochondrial membrane potential, ROS, and apoptosisHasini A Kalpage, Viktoriia Bazylianska, Maurice A Recanati, et al.
Cancer Research|March 15, 2008
Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibitionDuyen T Dang, Sang Y Chun, Kyunghee Burkitt, et al.
Pageof 25